How to Get Koselugo (selumetinib) Covered by Cigna in Pennsylvania: Prior Authorization Guide and Appeals Process
Answer Box: Getting Koselugo (selumetinib) Covered by Cigna in Pennsylvania
Koselugo (selumetinib) requires prior authorization from Cigna for pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas. Your prescriber must document NF1 diagnosis, imaging showing inoperable plexiform neurofibromas, baseline heart function (LVEF), and eye exam results. If denied, you can appeal through Cigna's internal process, then use Pennsylvania's new external review program, which overturns about 50% of denials.
First step today: Have your oncologist or neurologist gather your MRI showing plexiform neurofibromas, baseline echocardiogram, and eye exam, then submit the prior authorization through Cigna's provider portal or Express Scripts.
Table of Contents
- Coverage Requirements at a Glance
- Step-by-Step: Fastest Path to Approval
- Common Denial Reasons & How to Fix Them
- Appeals Process for Cigna in Pennsylvania
- Pennsylvania's External Review Advantage
- Clinician Corner: Medical Necessity Documentation
- Cost Assistance and Patient Support
- When Treatment Gets Interrupted
- FAQ: Koselugo Coverage in Pennsylvania
Coverage Requirements at a Glance
| Requirement | What It Means | Where to Find It | Source |
|---|---|---|---|
| Prior Authorization | Required before dispensing | Cigna provider portal or Express Scripts | Cigna PA Policy |
| Age Limit | Pediatric patients ≥2 years | FDA label, payer policies | FDA Approval |
| Diagnosis | NF1 with symptomatic, inoperable plexiform neurofibromas | Clinical notes, imaging | Koselugo PA Criteria |
| Prescriber | Oncologist or neurologist | Provider credentials | Common PA Requirements |
| Baseline Tests | LVEF (echocardiogram), eye exam | Lab/imaging results | FDA Label Safety |
| Renewal | Every 12 months with response documentation | Updated MRI, clinical notes | Renewal Criteria |
Step-by-Step: Fastest Path to Approval
1. Confirm Your Diagnosis Documentation
Who: Your oncologist or neurologist
What: Medical records showing NF1 diagnosis and MRI confirming symptomatic, inoperable plexiform neurofibromas
Timeline: Should already be in your medical record
2. Complete Required Baseline Testing
Who: Your medical team
What: Echocardiogram (LVEF assessment) and comprehensive eye exam
Timeline: Must be completed before starting treatment
Source: FDA safety requirements
3. Submit Prior Authorization
Who: Your prescriber's office
What: PA request through Cigna provider portal or Express Scripts (1-800-753-2857)
Timeline: Allow 72 hours for standard review, 24 hours for urgent requests
Required documents: Clinical notes, imaging, baseline test results
4. Track Your Request
Who: You or your clinic
What: Follow up if no response within the standard timeframe
Timeline: Cigna typically responds within 5-7 business days
5. If Approved: Fill Prescription
Who: Specialty pharmacy (likely Accredo through Express Scripts)
What: Coordinate delivery and administration instructions
Note: Koselugo requires specialty pharmacy dispensing due to its cost and monitoring requirements
6. If Denied: Begin Appeals Process
Who: You and your prescriber
What: File internal appeal within 30 days
Timeline: Internal appeals decided within 30-60 days depending on urgency
Common Denial Reasons & How to Fix Them
| Denial Reason | How to Overturn | Key Documents |
|---|---|---|
| "Not medically necessary" | Provide peer-reviewed evidence of MEK inhibitor efficacy in NF1-PN | FDA approval data, clinical trial publications |
| "Experimental/investigational" | Cite FDA approval (2020) for pediatric NF1 plexiform neurofibromas | FDA label |
| Missing baseline testing | Submit echocardiogram and ophthalmologic evaluation results | LVEF assessment, eye exam report |
| Age restriction | Confirm patient is ≥2 years old with appropriate documentation | Birth certificate, medical records |
| Prescriber not qualified | Have oncologist or neurologist submit/co-sign the request | Provider credentials, NPI verification |
Appeals Process for Cigna in Pennsylvania
Internal Appeals (First Level)
- Deadline: 30 days from denial notice
- How to file: Cigna member portal, phone (1-800-Cigna24), or written request
- Timeline: 30 days for standard review, 72 hours for urgent
- Required: Denial letter, additional clinical documentation, prescriber letter of medical necessity
Internal Appeals (Second Level)
- Automatic: If first appeal is denied
- Timeline: Additional 30 days for review
- Process: Independent medical reviewer evaluates case
Pennsylvania External Review
Pennsylvania's new external review program, launched in January 2024, has overturned approximately 50% of appealed denials in its first year.
Eligibility: After completing internal appeals and receiving Final Adverse Benefit Determination
Deadline: 4 months from final internal denial
How to apply: Pennsylvania Insurance Department website or call 1-877-881-6388
Timeline: 45 days for standard review, 72 hours for expedited
Cost: Free to consumers
Note: Pennsylvania's external review covers commercial insurance purchased directly, through Pennie, or employer-sponsored plans—but not self-funded employer plans.
Pennsylvania's External Review Advantage
Pennsylvania's independent external review process has proven particularly effective for specialty drug appeals. In the program's first six months, over 100 Pennsylvanians successfully appealed denied services, with independent medical reviewers overturning 53% of eligible cases.
Key advantages:
- State-supervised process with strict timelines
- Independent review organizations staffed by experienced physicians
- Binding decisions that insurers must honor immediately
- No cost to consumers
- Additional documentation allowed within 15 days of assignment
How it works:
- Complete Cigna's internal appeal process
- Submit external review request at pa.gov/reviewmyclaim
- Pennsylvania assigns independent review organization within 1 business day
- Submit additional supporting documentation within 15 days
- Independent medical experts issue binding decision within 45 days
Clinician Corner: Medical Necessity Documentation
Essential Elements for PA Success
Diagnosis Documentation:
- Confirmed NF1 diagnosis with genetic testing or clinical criteria
- ICD-10 code Q85.01 (Neurofibromatosis, type 1)
- Imaging demonstrating plexiform neurofibromas with measurements
Clinical Rationale:
- Documentation of symptoms (pain, functional impairment, cosmetic concerns)
- Evidence that plexiform neurofibromas are inoperable
- Treatment goals (symptom relief, prevention of progression)
Safety Prerequisites:
- Baseline LVEF assessment via echocardiogram or cardiac MRI
- Comprehensive ophthalmologic examination
- Documentation of no contraindications
Guideline Support:
- Reference FDA approval for pediatric NF1 plexiform neurofibromas
- Cite clinical trial data (SPRINT trial) showing efficacy
- Include relevant treatment guidelines from pediatric oncology societies
Sample Letter Template Points:
"[Patient] is a [age]-year-old with confirmed neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas documented by MRI on [date]. The patient experiences [specific symptoms] that significantly impact quality of life. Surgical resection is not feasible due to [anatomic location/risk factors]. Baseline cardiac function (LVEF [%]) and ophthalmologic evaluation are normal. Koselugo is FDA-approved for this exact indication and represents the standard of care for pediatric NF1 plexiform neurofibromas."
Cost Assistance and Patient Support
Koselugo Patient Support:
- Alexion Access Navigator: Financial assistance and PA support
- Phone: Contact through Koselugo.com resources
- Coverage investigation and appeals assistance
Estimated Costs:
- Annual treatment cost: Approximately $268,677 based on pediatric modeling
- Monthly pharmacy costs: $2,651-$6,617 depending on dose strength
- Actual costs vary by body surface area and insurance coverage
Additional Resources:
- Manufacturer copay assistance programs (verify eligibility)
- State pharmaceutical assistance programs in Pennsylvania
- Nonprofit foundation grants for rare disease treatments
When Treatment Gets Interrupted
Treatment interruptions may occur due to coverage gaps, prior authorization delays, or adverse reactions. Understanding the management approach helps maintain continuity of care.
Common Interruption Scenarios:
- Coverage lapses: During insurance changes or PA renewals
- Adverse reactions: Requiring dose holds for safety monitoring
- Prior authorization delays: Between approval periods
Management Strategies:
- For coverage gaps: Contact Alexion Access Navigator for bridge therapy options
- For safety holds: Follow FDA-approved monitoring protocols (echocardiograms every 3-6 weeks during LVEF recovery)
- For PA delays: Request expedited review if clinically urgent
From our advocates: We've seen families successfully navigate coverage interruptions by staying in close contact with both their specialty pharmacy and the manufacturer's patient support program. Having backup documentation ready—including recent imaging and response assessments—can significantly speed up reauthorization when switching insurance plans.
FAQ: Koselugo Coverage in Pennsylvania
How long does Cigna prior authorization take in Pennsylvania? Standard PA decisions typically take 5-7 business days. Urgent requests (when delay could jeopardize health) must be decided within 72 hours per Pennsylvania insurance regulations.
What if Koselugo is not on Cigna's formulary? Request a formulary exception by demonstrating medical necessity and lack of suitable alternatives. Your prescriber can submit this as part of the PA process.
Can I request an expedited appeal in Pennsylvania? Yes, if delay in treatment could seriously jeopardize your life or health. Both Cigna's internal process and Pennsylvania's external review offer expedited timelines (72 hours vs. standard 30-45 days).
Does step therapy apply to Koselugo? Generally no, as Koselugo was the first FDA-approved treatment specifically for NF1 plexiform neurofibromas in children. However, with the 2025 approval of mirdametinib (Gomekli), some plans may implement step therapy preferences.
What happens if I move out of Pennsylvania during treatment? Your Cigna coverage should continue, but you'll lose access to Pennsylvania's external review process. Check your new state's external review options and timeline requirements.
How often do I need prior authorization renewal? Typically every 12 months, with documentation of clinical response (stable or improved plexiform neurofibromas on MRI) and continued safety monitoring results.
Can adults get Koselugo covered? As of 2025, adults with NF1 plexiform neurofibromas may be directed to mirdametinib (Gomekli), which received FDA approval for both adult and pediatric patients. Check current formulary preferences.
About Counterforce Health: Counterforce Health specializes in helping patients, clinicians, and specialty pharmacies navigate complex prior authorization processes for specialty medications. Our platform analyzes denial letters and plan policies to create targeted, evidence-based appeals that align with payer requirements and improve approval rates for treatments like Koselugo.
If you're facing challenges with Koselugo coverage through Cigna, Counterforce Health can help streamline your appeals process by identifying the specific denial basis and crafting point-by-point rebuttals using the right clinical evidence and payer-specific requirements.
Sources & Further Reading
- Cigna Koselugo PA Policy (PDF)
- Pennsylvania External Review Process
- FDA Koselugo Approval and Label
- Koselugo Common PA Criteria
- Pennsylvania Insurance Department Consumer Services
- Koselugo Patient Resources
Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider regarding treatment decisions and work with qualified professionals for insurance appeals. Coverage policies and requirements may change; verify current information with your insurer and state insurance department.
Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.